Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Hospital for Joint Diseases, MS Care Center, New York

Winthrop University Hospital, Mineola

Upstate Clinical Research, Albany

Albany Medical Center, Albany

University of Rochester Medical Center, Rochester

University of Pennsylvania, Philadelphia

Maryland Center for MS, Baltimore

Raleigh Neurology Associates, Raleigh

MS Center/CMC Meyers Park, Charlotte

The Multiple Sclerosis Center of Atlanta, Atlanta

Neurology Associates, P.A., Maitland

University of Cincinnati, Cincinnati

Wayne State University MS Center, Detroit

Michigan State University, East Lansing

Michigan Medical P.C. Neurology, Grand Rapids

Consultants in Neurology, Northbrook

St. Louis University Hospital, St Louis

KUMC Neurology, Kansas City

Louisiana State University Health Sciences Center, Shreveport

The MS Center at Texas Neurology, Dallas

Central Texas Neurology, Round Rock

University of Utah CAMT, Salt Lake City

St. Joseph's Hospital and Medical Center, Phoenix

Mayo Clinic, Scottsdale

Sutter East Bay Medical Foundation, Berkeley

MS Hub Medical Group, Seattle

Wenatchee Valley Medical Center, Wenatchee

Rockwood Clinic, PS, Spokane

MS Center at Dartmouth, Lebanon

Gimble MS Center, Teaneck

Foothills Medical Centre-MS Research Program, Calgary

University of Alberta, Edmonton

Health Sciences Center, Winnipeg

London Health Sciences Centre, London

Clinique SEP/NM, Gatineau

Montreal Neurological Institute, Montreal